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Background: Edoxaban, a direct factor Xa inhibitor, is a once-daily, non-vitamin K antagonist oral anticoagulant.
There is no established method to reverse the activity of non-vitamin K oral anticoagulants in cases
of hemorrhage or urgent surgery. This study evaluated the ability of a 3-factor prothrombin complex concentrate
(3F-PCC) to reverse the anticoagulatory effects of edoxaban.
Methods: In this phase 1 study, 24 healthy subjects were randomly assigned to receive a single dose of 60 or
180 mg edoxaban, followed by placebo, 25 IU/kg 3F-PCC, or 50 IU/kg 3F-PCC. Edoxaban pharmacokinetics and
pharmacodynamics, including the primary endpoint of prothrombin time (PT) and endogenous thrombin poten-
tial (ETP), were assessed. D-dimer and prothrombin fragment 1 and 2 (F1+2) were also measured.
Results:Overall, therewere no apparent consistent effects of 3F-PCC on edoxaban pharmacokinetics. Administration
of 3F-PCC 25 or 50 IU/kg with edoxaban 60 or 180 mg did not substantially accelerate the return of PT to baseline
levels. However, infusion of 3F-PCC 25 and 50 IU/kg did substantially accelerate return to baseline of ETP compared
with placebo. D-dimer and F1+2 data did not indicate any lasting procoagulant effects of 3F-PCC infusion, although
a transient increase in F1+2 was noted during and after 3F-PCC infusion. Edoxaban and 3F-PCC co-administration
was well tolerated in normal healthy subjects.
Conclusions: There was no apparent reversal of PT prolongation with 3F-PCC following edoxaban infusion, but ETP
was completely reversed. Co-administration of 3F-PCC was well tolerated, but a dose-dependent increase in
F1+2 may reﬂect a procoagulant risk.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Edoxaban is an oral, once-daily, direct factor Xa (FXa) inhibitor [1]
that has been approved in the United States and Japan and has been sub-
mitted for approval in other countries, including the European Union [2,
3]. It has a faster onset and offset of action andmore predictable pharma-
cokinetics (PK) comparedwithwarfarin [4,5]. Aswith other non-vitamin
K antagonist oral anticoagulants (NOACs), there is no established stan-
dard for reversing the anticoagulant effect of edoxaban in patients in
need of urgent surgery or experiencing clinically relevant bleeding.
Prothrombin complex concentrates (PCCs) are intermediate-purity,
pooled plasma products that contain a mixture of 3 or 4 vitamin
K-dependent coagulation factors, standardized based on factor IX
activity or content [6,7]. They are approved globally for the control ofelopment, 399 Thornall Street,
. This is an open access article underspontaneous bleeding [7,8] or the prevention of bleeding in patients
with hemophilia B [9]. PCCs have been investigated for their ability
to reverse the anticoagulant effect of direct factor IIa or Xa inhibitors
[8,10–17]. Both 3-factor (3F-PCC) and 4-factor PCCs (4F-PCC) have
been investigated for reversal of NOAC activity in vivo [13–15]. A
4F-PCC dose of 50 IU/kg reversed the effects of twice-daily
rivaroxaban 20 mg on day 3 of treatment as measured by anticoagu-
lant assays [13]. Administration of PCC returned the anticoagulation
biomarkers prothrombin time (PT) and endogenous thrombin po-
tential (ETP; the area under the thrombin generation curve) to base-
line levels [13]. In a study subsequent to the work presented here, we
demonstrated that a 4F-PCC dose of 50 IU/kg also completely reverses
the effects of a single dose of edoxaban on ETP and bleeding time after
a punch biopsy, and partially reverses the effects on PT [15]. In both
studies, PCC increased ETP above baseline at later time points [13,15],
suggesting the possibility of late-onset procoagulant effects due to
factors of prothrombin complex present in the PCC. The current study
evaluated the ability of a 3F-PCC (Bebulin® VH, Baxter Healthcarethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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effect of edoxaban as measured by pharmacodynamic (PD) markers
of coagulation, including PT and ETP.
2. Materials and Methods
2.1. Study Design and Objectives
Thiswas a phase 1, single-dose, placebo-controlled, 3-way crossover
study conducted in 2 parallel cohorts. The study was conducted over
a period of 16 ± 1 weeks (Fig. 1). The protocol was approved by an
institutional reviewboard (Chesapeake Research Review, Inc, Columbia,
MD) and conducted in compliance with the Declaration of Helsinki and
the International Conference on Harmonisation Consolidated Guideline
E6 for Good Clinical Practice. All subjects gavewritten informed consent
prior to screening.
Enrolled normal healthy subjects were randomly assigned to 1 of 2
dosing cohorts: single-dose edoxaban 60 mg (cohort 1) or single-dose
edoxaban 180 mg (cohort 2). Within each cohort, subjects were
randomized to 1 of 6 treatment sequences (Sequence 1: ABC,
Sequence 2: BCA, Sequence 3: CAB, Sequence 4: ACB, Sequence 5:
BAC, Sequence 6: CBA). The randomization schedule was generated
by a statistician. All personnel involved in the study conduct and
data review were blinded to the schedule. An unblinded dispensing
pharmacist provided treatments but was otherwise uninvolved
with the study. Each treatment consisted of a single, oral dose of
edoxaban followed 1 h later by a 1.5- to 2-h intravenous infusion of
placebo (Treatment A), 3F-PCC 25 IU/kg (Treatment B), or 3F-PCC
50 IU/kg (Treatment C). The 3F-PCC was administered at a concentration
of 2 IU/mL. Infusion times were 1.5 h for subjects weighing 57 to
85 kg and 2 h for subjects weighing N85 to 110 kg. Each dose of
edoxaban was separated by a washout period of ≥14 days as deter-
mined by the half-life of the principal plasma factors in Bebulin®
[18].
Edoxaban 60 mg was studied in phase 3 clinical trials for the
treatment of nonvalvular atrial ﬁbrillation and for the treatment of ve-
nous thromboembolism. A 50 IU/kg dose of 3F-PCC was chosen as this
dose has been shown to completely reverse the effects of rivaroxaban
on PT and ETP [14]. The 3F-PCC 25 IU/kg dosewas selected to determine
if a lower dose would provide sufﬁcient reversal and produce less of a
procoagulant signal than 50 IU/kg.
The primary objective of this study was to evaluate the reversal
effects of 25- and 50-IU/kg doses of 3F-PCC using PT as the primary PD
marker, following a single oral 60- or 180-mg dose of edoxaban.
Additional markers of coagulation included ETP, D-dimer, and
prothrombin fragment 1+2 (F1+2). In addition, the impact of 3F-
PCC administration on edoxaban PK was assessed.Fig. 1. StudyDesign. ↑, dose day; oral edoxaban (cohort 1, edoxaban60mg; cohort 2, edoxaban 1
3-factor prothrombin complex concentrate (3F-PCC; Treatment B), or 50 IU/kg of 3F-PCC (Treat
Sequence 3: CAB, Sequence 4: ACB, Sequence 5: BAC, Sequence 6: CBA. For each sequence, n =
infusion of placebo starting at 1 h postdose; Treatment B: Single oral dose of edoxaban at h 0 o
Treatment C: Single oral dose of edoxaban at h 0 on day 1, followed by an intravenous infusion2.2. Subjects
Healthy men and nonpregnant/nonbreastfeeding women aged 18 to
45 yearswith a bodymass index (BMI) of 21 to 32 kg/m2 and aweight of
50 to 110 kg were eligible for study enrollment. Subjects were excluded
if theywere prescribed anymedication or herbal supplementswithin the
past 14 days, or had taken St. John’s wort, strong inducers or inhibitors of
cytochrome p450 enzymes, or strong inducers or inhibitors of
P-glycoprotein within the past 30 days. The use of anticoagulants in
the 30 days prior to the start of testing, a family history of abnormal
bleeding or clotting, major surgery in the last 6 months, a history of
minor bleeding, a history of gastrointestinal bleeding or ulcer, or sensitiv-
ity to edoxaban or similar products were also conditions for exclusion. In
addition, subjects were excluded if they had factor V Leiden mutation or
other predispositions for clotting, bleeding, deep-vein thrombosis or pul-
monary embolism due to inherited or acquired risk factors. Subjects
were ineligible for the study if they were carriers of hepatitis B surface
antigen (HbsAg), hepatitis C antibody (HCV), or human immunodeﬁ-
ciency virus types 1 or 2 (HIV-1, HIV-2). Since PCC is derived from
human blood, subjects were tested for HIV-1 and 2, HbsAg, anti-HCV,
hepatitis A, and parvovirus B19V at various times during the study.
2.3. Sample Collection
For determination of edoxaban plasma concentrations and PDmea-
sures, blood samples were collected from the subject’s upper extremity
not used for the PCC infusion. Blood samples for PK assessment were
obtained at approximately 1 h prior to edoxaban dosing and at 0.5, 1,
1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 60, and 72 h after the edoxaban
dose. PK blood samples were obtained by direct venipuncture, collected
in lithium heparin tubes, mixed by gentle inversion, and placed on ice.
Within 45 min of collection, tubes were centrifuged at 1500 g for
10 min at 4 °C. The plasma layer was removed, divided into aliquots
and stored at -20 °C until assayed at Quintiles Bioanalytical and ADME
Laboratories (formerly Advion Bioservices, Ithaca, NY). PD blood
samples were obtained by direct venipuncture, collected in citrated
tubes, mixed by gentle inversion, and placed on ice. Within 30 min of
collection, tubes were centrifuged at 2500 g for 15 min. Samples were
kept on ice while the plasma layer was removed and divided into
aliquots that were stored at -70 °C until assayed at Medpace Reference
Laboratories (Cincinnati, OH).
2.4. Bioanalysis and Pharmacokinetic Assessments
Free-base plasma concentrations of edoxaban were analyzed by
Advion BioServices using a liquid chromatography separation with a
tandem mass spectrometer detection method. Analytes and standards80mg) administered 1 h before intravenous infusion of placebo (TreatmentA), 25 IU/kg of
ment C). Duration of treatment infusionwas 1.5 to 2 h. Sequence 1: ABC, Sequence 2: BCA,
4. Treatment A: Single oral dose of edoxaban at h 0 on day 1, followed by an intravenous
n day 1, followed by an intravenous infusion of 25 IU/kg 3F-PCC starting at 1 h postdose;
of 50 IU/kg 3F-PCC starting at 1 h postdose.
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mode cation exchange resin) 96-well solid-phase extraction plates
(Waters Corporation, Milford, MA). Analysis of extracted samples was
performed by gradient chromatography using a Zorbax Eclipse XDB
Phenyl (50 mm x 2.1 mm, 5 μm; Agilent Technologies, Santa Clara,
CA) column. Analytes and standards were detected using a Sciex API
4000 triple quadrupole spectrometer (Sciex, Framingham, MA) with
TurboIonSpray source (Sciex) in positive ionization mode. Edoxaban
was quantiﬁed using a quadratic (1/X2 weighting) calibration curve
ranging from 0.764 to 382 ng/mL. PK parameters were calculated
from the individual plasma concentrations of edoxaban using a
noncompartmental approach. The parameters measured include the
area under the plasma concentration-time curve from the time of dos-
ing extrapolated to inﬁnity (AUC0-inf), the maximum (peak) observed
concentration in plasma (Cmax), the time of maximum observed
concentration (Tmax), and the apparent terminal half-life (T1/2).2.5. Pharmacodynamic Assessments
PT was measured using the thromboplastin preparation Neoplastin
C1+ on a Stago platform (STA, Neoplastin C1 Plus®; Diagnostica
Stago, Parsippany, NJ). ETP was measured using the thrombin genera-
tion assay (Technoclone, Vienna, Austria). Anti-FXa was measured
using the Biophen heparin 6 assay (Hyphen BioMed, Neuville-sur-
Oise, France), a chromogenic kinetics assay in which a chromogenic
substrate is hydrolyzed by excess factor Xa, run in duplicate on the
Siemens BCS (Siemens Healthcare Diagnostics, Tarrytown, NY).
Procoagulant activity was assessed by D-dimer, a measure of endoge-
nous thrombus turnover, and the prothrombin cleavage products
F1+2, an indirect measure of endogenous thrombin generation. Both
D-dimer and F1+2 were measured by enzyme-linked immunosorbentFig. 2. Edoxaban Plasma Concentration vs Time Curves for A) Cohort 1 (Edoxaban 60mg) and B
difﬁcult venipunctures. Inset ﬁgure is a log plot of treatment. Error bars indicate standard deviassay. All assays were conducted using validated methods by Medpace
Reference Laboratories.
Mean values and change from baseline were assessed for all PD
measures. Percent change from baseline was assessed for ETP. Also
calculated were the PD parameters Amin and Amax, the minimum and
maximum observed activity values; ΔAmin and ΔAmax, the change
from baseline to Amin and Amax values; %ΔAmin and %ΔAmax, the percent
change from baseline to Amin and Amax values; and Tmax, the time of
maximal activity after the dose of edoxaban.
2.6. Safety
Adverse events (AEs) were recorded throughout the study. Follow-
up virology testing was performed at checkout for subjects discharged
early and at 2 and 12 weeks after checkout for all other subjects.
Subjects were tested for hepatitis A and parvovirus B19V 2 weeks
after discharge, and tested for HIV-1 and 2, hepatitis B, and hepatitis C
at 12 weeks after checkout.
2.7. Statistical Analysis
Demographic and baseline characteristics were summarized by
descriptive statistics. All PK concentrations and parameters, along with
PD raw values, the change from baseline and the percent change from
baseline, were summarized by treatment for each cohort with descrip-
tive statistics. The change in PT from baseline to each time point after
the start of 3F-PCC dosing was estimated within each treatment in
each cohort, and a 95% conﬁdence interval (CI) was calculated. If the
95% CI was contained within the interval of -1 to 1, it was interpreted
that the PT had reversed to baseline. Treatment differences in
baseline-adjusted PT after the start of 3F-PCC dosing were evaluated
at every time point within each cohort using an analysis of covariance) Cohort 2 (Edoxaban 180mg). *One subjectwas dropped after the 2.5-h time point due to
ation. 3F-PCC = 3-factor-prothrombin complex concentrate.
Fig. 3. Mean Change from Pre-Edoxaban Baseline in Prothrombin Time for A) Cohort 1
(Edoxaban 60 mg) and B) Cohort 2 (Edoxaban 180 mg). *One subject was dropped
after the 2.5-h time point due to difﬁcult venipunctures. Inset ﬁgure shows data without
standard deviation. Error bars indicate standard deviation. 3F-PCC = 3 factor-prothrom-
bin complex concentrate; PT = prothrombin time.
828 K.S. Brown et al. / Thrombosis Research 136 (2015) 825–831model for crossover design with pre-3F-PCC dosing and baseline as
covariates. Analyses were performed using SAS PROC MIXED with
sequence, period, treatment, hour, treatment by hour, baseline, and
predose 3 F-PCC values as ﬁxed effects and the random effect of subject
within sequence.
A sample size of 10 completed subjects per treatment group was
calculated to be sufﬁcient to provide 80% power for a difference in
means of 0.2 ± 1.13 sec assuming an equivalence margin of 1.0 (~10%
baseline PT change) and α= 0.05. Twelve subjects were enrolled in
each cohort to ensure that 10 subjects would complete the study.
3. Results
3.1. Subject Description
Of the 24 subjects (20 men, 4 women) enrolled, 2 subjects
discontinued during the in-clinic period, 2 subjects were lost to
follow-up before completing virology testing, and 20 subjects
completed the study and follow-up virology testing. Mean height,
weight, age, and BMI were balanced between cohorts (Supplemental
Table S1).
3.2. Edoxaban Pharmacokinetic Parameters
Mean edoxaban concentrations followed similar time curves follow-
ing 3F-PCC treatment when administered to subjects in cohort 1
(edoxaban 60 mg; Fig. 2A). The mean plasma concentrations were
slightly lower 1.5 to 8 h postdose for 3F-PCC 25 IU/kg compared
with 3F-PCC 50 IU/kg or placebo. Cmax and AUC0-inf values did not differ
signiﬁcantly between 3F-PCC treatment groups. Neither of the 3F-PCC
infusion doses in this cohort affected the total (AUC) or the Cmax of
edoxaban compared with placebo (Supplemental Table 2).
The higher dose of edoxaban (180 mg) produced higher Cmax
and AUC0-inf values for edoxaban in cohort 2 compared with cohort 1
(Supplemental Table 2). Mean edoxaban concentrations were similar
after placebo and infusion of 3F-PCC 50 IU/kg, but were notably lower
following treatment with 3F-PCC 25 IU/kg (Fig. 2B). Because this
effect was only observed in the 25 IU/kg arm and only for 180 mg
edoxaban, it was not considered evidence for an effect of 3F-PCC on
edoxaban PK.
3.3. Pharmacodynamic Analyses
3.3.1. Prothrombin Time
In cohort 1 (edoxaban 60 mg), infusion of both 3F-PCC 25 and
50 IU/kg resulted in modestly lower PT values during the ﬁrst 6 h
of treatment compared with placebo (Fig. 3A). As expected,
edoxaban treatment dose-dependently prolonged Amax, and %ΔAmax.
Taking into consideration PT variability, Amax, and %ΔAmax, values
were comparable for placebo, 3F-PCC 25 IU/kg, and 3F-PCC 50 IU/kg
(Table 1). The Amax for placebo was 20.0 ± 3.2 sec; 3F-PCC 25 IU/kg
was 19.5 ± 2.8 sec, and 3F-PCC 50 IU/kg was 19.3 ± 3.2 sec; the
ΔAmax values were 56.2 ± 27.0%, 52.8 ± 24.8%, and 51.7 ± 29.5% for
placebo, 3F-PCC 25 IU/kg, and 3F-PCC 50 IU/kg, respectively.
PT returned to baseline levels by 24 h postdose following infusion of
3F-PCC 25 or 50 IU/kg, and by 72 h following infusion of placebo.
In cohort 2 (edoxaban 180mg), infusion of 3F-PCC 25 IU/kg resulted
in noticeably lower PT values comparedwith placebo during theﬁrst 6 h
of treatment (Fig. 3B), consistent with the lower edoxaban exposure
observed in this treatment group. In contrast, PT values following
the 3F-PCC 50 IU/kg infusion were similar to placebo; this effect was
consistent with the comparable edoxaban exposures observed in
these groups. The lowest Amax and %ΔAmax PT values occurred in the
3F-PCC 25 IU/kg infusion arm, again consistent with the decreased
edoxaban exposure in this treatment relative to the other 2 treatments
in cohort 2 (Table 1). PT parameters were comparable afteradministration of 3F-PCC 50 IU/kg and placebo (Table 1). Prothrombin
time reversed to baseline at 48 h following 3F-PCC 25 IU/kg and at
36 h following 3F-PCC 50 IU/kg; PT did not reverse to baseline following
infusion of placebo by the ﬁnal time point at 72 h. None of the 3F-PCC
treatments accelerated reversal of edoxaban-mediated PT prolongation
relative to placebo to a clinically relevant extent.
3.3.2. Thrombin Generation
As expected, edoxaban dose-dependently decreased ETP Amin and
%ΔAmin, with mean %ΔAmin values of 39.2 ± 21.3 following 60 mg
edoxaban with placebo (Table 1) and 50.0 ± 13.2 following 180 mg
edoxaban with placebo (Table 1).
In cohort 1 (edoxaban 60 mg), the %ΔAmin reductions in ETP were
consistent with edoxaban inhibition of thrombin generation for all
treatments, although ETP was reduced somewhat less in the presence
of 3F-PCC as compared with placebo (Table 1). Mean ETP values
returned to baseline within 36 h for the placebo treatment, 2.75 h for
the 3F-PCC 25 IU/kg and 2.50 h for the 3F-PCC 50 IU/kg infusions,
indicating rapid reversal of the effects of edoxaban (Fig. 4A, Table 1).
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treatments. Treatmentwith 3F-PCC increased themean percent change
from baseline to the maximum observed ETP (%ΔAmax) dose depen-
dently to a maximum of 32.9 ± 11.1% above baseline for 3F-PCC
50 IU/kg (Table 1).
In cohort 2 (edoxaban 180 mg), the mean percent ETP reductions
from baseline (%ΔAmin) were -50.0% for placebo, -38.8% for 3F-PCC 25
IU/kg, and -57.4% for 3F-PCC 50 IU/kg (Table 1). The lower ΔAmin seen
with 3F-PCC 25 IU/kg reﬂects the decreased exposure observed for
this treatment. Mean ETP values returned to baseline within 3.0 h
after the 3F-PCC 25 and 50 IU/kg infusions, while mean ETP values
had not fully returned to baseline by the last sampling time (72 h) for
infusions of placebo. This demonstrates rapid reversal of the effects of
edoxaban with both doses of 3F-PCC. The 3F-PCC treatment in cohort
2 increased the %ΔAmax to a similar degree as that seen in cohort 1.
Again, Tmax was shorter following 3F-PCC treatment (Table 1).
3.3.3. Anti-Factor Xa
3F-PCC had no effect on the ex vivo anti-FXa activity of plasma from
edoxaban-treated subjects. There were no differences between the 3
treatments in change from baseline anti-FXa to pre-3F-PCC dosing
following 60- and 180-mg edoxaban doses. For both cohorts, baseline
anti-FXa concentrations were below the lower limit of quantiﬁcation,
and were set at 0.05 IU/mL. In cohort 1, the maximum anti-FXa values
were 2.55 ± 1.0 IU/mL for placebo, 2.66 ± 1.0 IU/mL for 3F-PCC 25 IU/
kg, and 2.36 ± 1.3 IU/mL for 3F-PCC 50 IU/kg; in cohort 2, the
maximum anti-FXa values were 5.28 ± 1.2 IU/mL for placebo, 3.77 ±
1.4 IU/mL for 3F-PCC 25 IU/kg, and 5.98 ± 1.8 IU/mL for 3F-PCC 50 IU/
kg. The lower anti-FXa values following 3F-PCC 25 IU/kg in the
180 mg cohort were consistent with the reduced edoxaban exposure
seen for this treatment.
3.3.4. Procoagulant activity
Administration of either edoxaban 60 or 180mgwith 3F-PCC had no
clinically signiﬁcant effect on D-dimer (Supplemental Figure S1).
Administration of either edoxaban 60 or 180 mg resulted in a transient,
3F-PCC dose-dependent increase in F1+2 thatmay reﬂect procoagulant
effects of 3F-PCC (Supplemental Figure S2).Table 1
Pharmacodynamic Parameters of Prothrombin Time and Endogenous Thrombin Potential.
Cohort 1 (Edoxaban 60 mg)
Edoxaban + Placebo
n = 12
Edoxaban +3F-PCC
(25 IU/kg)
n = 12
Edoxaba
(50 IU/kg
n = 12
Prothrombin time
Baseline, sec 12.8 ± 0.47 12.8 ± 0.43 12.7 ± 0
Amin, sec 12.7 ± 0.44 12.4 ± 0.31 12.2 ± 0
Amax, sec 20.0 ± 3.2 19.5 ± 2.8 19.3 ± 3
%ΔAmax, % 56.2 ± 27.0 52.8 ± 24.8 51.7 ± 2
Tmax, sec 1.25
(1.00, 3.50)
1.00
(0.50, 1.50)
1.00
(0.50, 2.5
Endogenous Thrombin Potential
Baseline, nM · min 4720 ± 370 4590 ± 430 4670 ± 3
Time of Return to Baseline
(or higher) ETP, h
36
(0.5, N60)
2.75
(0.5, 8.0)
2.5
(1.5, 3.0)
Amin, nM · min 2850 ± 1030 3200 ± 800 3110 ± 1
%ΔAmin, % -39.2 ± 21.3 -31.0 ± 13.6 -33.0 ± 2
Amax, nM · min 4840 ± 480 5550 ± 350 6190 ± 5
% ΔAmax, % 3.12 ± 11.5 21.6 ± 11.0 32.9 ± 1
Tmax, h 42.0
(0.5, 60.0)
12.0
(4.0, 60.0)
12.0
(2.5, 60.0
* One subject was dropped after the 2.5-h time point due to difﬁcult venipunctures. #N/A – No
All values are reported as mean ± standard deviation, with the exception of Tmax and time to
%ΔAmax = percent change from baseline in the maximum observed activity; %ΔAmin = per
thrombin complex concentrate; Amax =maximum observed activity; Amin =minimum ob
observed activity.3.4. Safety
No deaths or serious AEs occurred in this study. A total of 4 subjects
in cohort 1 experienced 12 treatment-emergent AEs, and 6 subjects in
cohort 2 experienced 13 treatment-emergent AEs. Adverse events re-
ported in cohort 1 included abdominal discomfort, abdominal pain, con-
stipation, nausea, contusion, laceration, musculoskeletal discomfort,
headache, dysmenorrhea, metrorrhagia, and pruritic rash (n = 1,
each). In cohort 2, AEs reported were laceration and headache (n = 2,
each), constipation, vomiting, hunger, vessel puncture site pain, de-
creased hemoglobin, limb discomfort, and extremity pain (n = 1,
each). All treatment-emergent AEs occurred following the combination
of edoxaban and 3F-PCC and were mild in severity. One AE, a mild con-
tusion on the biceps approximately 8 days following co-administration
of edoxaban and placebo that resolved within 7 days without treat-
ment, was considered by the investigator to be related to the study
treatment. One subject was discontinued from the study due to a de-
crease in hemoglobin, possibly related to the large number of blood
draws as the subject had no clinical or laboratory signs of bleeding.
As indicated by follow-up virology testing, no subjects
seroconverted for HIV-1 and 2, HbsAg, anti-HCV, hepatitis A, or par-
vovirus B19V as a result of 3F-PCC treatment.
4. Discussion
4.1. Pharmacokinetics
Overall, there was no apparent consistent effect of 3F-PCC on
edoxaban PK. Exposures following the edoxaban 60-mg dose were
similar to those observed in other studies in healthy volunteers [5].
Following edoxaban 180mg and placebo or 3F-PCC 50 IU/kg, edoxaban
exposures were again similar to those observed in other studies in
which the same dose of edoxabanwas administered to healthy subjects
[19]. However, edoxaban Cmax and AUC were lower following adminis-
tration of 3F-PCC25 IU/kgwith edoxaban180mgas comparedwith pla-
cebo. This decreased exposure was reﬂected in the PD data for this
treatment. The fact that only treatment with 3F-PCC 25 IU/kg following
edoxaban 180 mg showed decreased exposure suggests that this
decrease may be due to the variability inherent in studies with smallCohort 2 (Edoxaban 180 mg)
n +3F-PCC
)
Edoxaban + Placebo
n = 12*
Edoxaban +3F-PCC
(25 IU/kg)
n = 10
Edoxaban +3F-PCC
(50 IU/kg)
n = 11
.48 12.8 ± 0.63 12.9 ± 0.44 13.0 ± 0.57
.41 12.9 ± 0.48 12.7 ± 0.51 12.6 ± 0.50
.9 27.0 ± 2.8 23.4 ± 4.2 27.0 ± 3.5
9.5 111 ± 20.4 81.6 ± 32.7 108 ± 25.1
0)
1.75
(1.00, 2.50)
1.00
(0.50, 2.50)
1.50
(1.00, 3.00)
50 4312 ± 460 4412 ± 620 4385 ± 620
N/A#
(36, N60)
3.0
(2.0, 8.0)
3.0
(2.0, 4.0)
190 2160 ± 590 2750 ± 1040 1800 ± 890
5.3 -50.0 ± 13.2 -38.8 ± 20.7 -57.4 ± 23.7
40 4830 ± 750 5170 ± 500 5750 ± 610
1.1 0.956 ± 11.3 18.4 ± 12.6 32.4 ± 13.7
)
54.0
(0.5, 60.0)
8.00
(3.0, 60.0)
12.0
(6.0, 60.0)
t achieved, value did not return to baseline levels.
return to baseline, which is represented as median (min, max).
cent change from baseline in the minimum observed activity; 3F-PCC= 3 factor-pro-
served activity; ETP = endogenous thrombin potential; Tmax = the time of maximum
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at 180 mg. Given edoxaban’s minimal accumulation at steady state
(accumulation ratio of 1.14) [3], results of this study are expected to
extrapolate to patients who are being maintained on the clinically
recommended dose of 60 mg edoxaban.
4.2. Pharmacodynamics
Administration of 3F-PCC 25 or 50 IU/kg with edoxaban 60 or
180 mg did not accelerate reversal of PT prolongation to a clinically
relevant extent. In contrast, for both doses of edoxaban, infusion of 3F-
PCC 25 and 50 IU/kg rapidly reversed the inhibition of ETP by edoxaban
comparedwith placebo. The increases in ETP%ΔAmaxwith 3F-PCC treat-
mentmay reﬂect a potential procoagulant effect of 3F-PCC ormay be an
assay artifact related to excess prothrombin (factor II, a component of
3F-PCC) in plasma samples from 3F-PCC-infused subjects. Thrombin
generation is a very sensitive assay, and thus all ETP measurements
showed variability.
The disparity between PT and ETP results is not understood, but
has been observed previously in a rivaroxaban reversal study usingFig. 4.Mean Percent Change from Pre-Edoxaban Baseline in Thrombin Generation –
Endogenous Thrombin Potential for A) Cohort 1 (Edoxaban 60 mg) and B) Cohort 2
(Edoxaban 180 mg). *One subject was dropped after the 2.5-h time point due to dif-
ﬁcult venipunctures. Error bars indicate standard deviation. 3F-PCC = 3 factor-pro-
thrombin complex concentrate; ETP = endogenous thrombin potential.both 3 and 4F-PCC [14]. Infusion of a 4F-PCC completely reverses
edoxaban effects on ETP, but not PT [15]. These conﬂicting data under-
score the difﬁculties in interpreting biomarker results in the setting of
NOAC treatment. No clinical bleeding studies have deﬁnitively
established which biomarker better correlates with actual bleeding.
However, a punch biopsy model demonstrated a dose-dependent in-
crease in bleeding duration following edoxaban administration. In this
study, less bleeding correlated well with reversal of ETP but not PT
[15]. These data suggest ETP may be more predictive of clinical reversal
of anticoagulation effects with a 3F-PCC.
Neither the 3F-PCC 25 IU/kg nor the 3F-PCC 50 IU/kg dose had any
reversal effect on anti-FXa when compared with placebo. This result
was expected, given that the anti-FXa assay measures the ability of
edoxaban to inhibit exogenously added FXa, not ex vivo-activated
endogenous FXa, and demonstrates that this assay is not appropriate
for assessing the reversal of FXa inhibitor-induced anticoagulation by
3F-PCC.
The infusion of 3F-PCCwas associatedwith increased thrombin gen-
eration (ETP and peak thrombin) relative to baseline, which persisted
for 72 h postdose. This ﬁnding is consistent with the infusion of factor
II, whichwould be expected to increase measured ETP and peak throm-
bin in the thrombin generation assay. The half-life for exogenously
infused factor II is approximately 60 h [20], which is consistent with
the persistence of the effect out to the last sampling point at 72 h.
While these data might suggest a procoagulant effect, the D-dimer
and F1+2 data are not indicative of lasting procoagulant effects of 3F-
PCC infusion in healthy subjects. A transient procoagulant effect of 3F-
PCC infusionmay be suggested by the increase in F1+2 observed during
and immediately after the infusion. Transient increases in F1+2without
D-dimer increases have previously been noted following PCC infusion
[15,21–23]. In some of these studies, PCC was also associated with
other indicators of procoagulant effects, including increasedﬁbrin depo-
sition [21] and the thrombin generationmarker thrombin-antithrombin
complex [23].
PCC infusion at 50 IU/kg has been shown to reverse rivaroxaban-
induced prolongation of PT and ETP [13], and the equivalent of a PCC
25 IU/kg dose has also been shown to recover ETP to near baseline
values in an ex vivo study [11]. PCC infusion of 50 IU/kg also reverses
edoxaban effects on ETP but not PT [15]. In these studies, it should be
noted that the PCCs chosen were 4F-PCCs. Both 3 and 4F-PCCs contain
factors II, IX, and X, however, 4F-PCCs also contain factor VII. The PCC
in this study, Bebulin®, contains 24-38 IU/mL factor IX, 24-38 IU/mL fac-
tor II, and 24-38 IU/mL factor X, as well as b5 IU/mL factor VII and
b0.15 IU heparin/IU factor IX [24]. In the setting of warfarin
anticoagulation, the presence of factor VII is important to fully reconsti-
tute the clotting system. This is reﬂected in the relative efﬁcacy of the 3-
vs 4-factor formulations [14]. Both 3 and 4F-PCC preparation are stan-
dardized based on factor IX content, and so different PCC formulations
may vary in the presence and concentrations of various anticoagulant
additives including protein C, protein S, protein Z, and heparin [25].
These differences may affect the relative ability of different PCC formu-
lations to reverse the anticoagulant effects of the NOACs.
This study suggests that a 3F-PCC may work as well as a 4F-PCC to
stop acute bleeding in a patient on edoxaban, because the biomarker
that best associated with bleeding in our 4F-PCC study, ETP, was
also completely reversed by a 3F-PCC [15]. However, data in clinically
bleeding patients treatedwith edoxabanwould be necessary to conﬁrm
this supposition.
4.3. Other Approaches for Reversal
Other approaches under evaluation for the reversal of NOACs in-
clude the use of activated PCC (Factor VIII Inhibitor Bypassing Activity
[FEIBA]) and the recombinant active form of factor VII [8,11,17,26].
FEIBA and recombinant activated factor VII are designed as hemostatic
agents for bleeding and hemostatic defects, not as reversal agents for
831K.S. Brown et al. / Thrombosis Research 136 (2015) 825–831direct FXa inhibition. These agents have been evaluated in a rat model
and in a human ex vivo study in which they were found to provide
signiﬁcant but partial reversal based on PT and aPTT [17,26]. The clinical
signiﬁcance of these results is not clear. Additionally, the synthetic
small molecule PER977 [27–30]; PRT064445 (andexanet alfa) [30–32],
a human recombinant FXa that has beenmodiﬁed to be catalytically in-
active; and an antibody fragment (idarucizumab) speciﬁc to dabigatran
are currently under investigation [33–36]. These agents are expected to
have minimal procoagulant effects, although PRT064445 has been
shown to bind tissue factor pathway inhibitor [32].
There was no apparent reversal of PT prolongation with this
3F-PCC following edoxaban administration. In contrast, the 3F-PCC
completely reversed ETP. As ETP correlated better with bleeding fol-
lowing punch biopsy [15], ETP is considered the more reliable bio-
marker. Co-administration of 3F-PCC with edoxaban was well
tolerated in normal healthy subjects, although a transient and 3F-PCC
dose-dependent increase in F1+2was observed and may reﬂect a pos-
sible procoagulant risk.
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